Transforming the lives of patients with diabetes and obesity by developing safe and effective weight loss therapies
Latest news
Zihipp signs exclusive license and option agreements for Imperial College obesity and diabetes programmes
Zihipp Limited, a UK-based biopharmaceutical company focused on the development of peptide hormones for the treatment of diabetes and obesity, announces it has signed an exclusive license and option agreements with Imperial College London.
The exclusive license includes the pre-clinical and clinical data packages for two oxyntomodulin and PYY analogue programmes which have successfully completed phase I clinical trials, along with several GLP-1, PYY and oxyntomodulin discovery programmes.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.